Professional Documents
Culture Documents
120
100
N=39
80
N=51
Non-blacks
60
Blacks
40
p=0.007
20
0
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5
Years from renal biopsy
M Dooley et al, Kidney Int 1997; 51:1188-1195
Renal Survival by Race at UNC
Independent of the following factors:
Age
Duration of SLE
History of hypertension
Majority
African
American
cohorts
Majority
caucasian
cohorts
Proportion without
1.0
Proportion without
relapse
0.6 22% failed to remit after 2 yr 0.6
0.4 0.4
0.2 Median time 79 mo
0.2 20% relapse after 18 mo
0.0 0.0
0 20 40 60 80 100 120 0 20 40 60 80 100 120
Time (mo from starting IV CYC) Time (mo from starting IV CYC)
Re-remission
Proportion without
1.0
re-remission
50
p = NS
40
p = 0.005
21/7 21/69
30 1 17/69
16/71
20
10 4/69
0
Complete Remission Partial Remission Complete + Partial
Remission
MMF IVC
Study endpoints
MMF IVC
Number randomized 71 69
Complete remission 16 4
Partial remission 21 17
No remission at 24 weeks on initial
19 21
regimen
Crossover to alternate regimen 6 12
Withdrawal from study 9 15
Study withdrawals
MMF IVC
6 early
13 early
5 severe disease
3 treatment refusals
1 non-compliance (1 death)
3 late 3 severe disease
• 2 crossover refusals (2 deaths)
• 1 toxicity (rash) 6 non-compliance
(2 with GI toxicity)
No deaths
1 lymphopenia
2 late
2 lost to follow-up
University of Miami Study Methods:
Study design & patient population
Open label, randomized clinical trial
Inclusion criteria
Adults > 18 years of age, World Health Organization (WHO) classes III, IV,
V with proliferation
Exclusion criteria
Have received IVCY > 7 doses or AZA > 8 weeks
Creatinine clearance < 20 mL/min
Pregnancy
Any clinically significant infection within 2 weeks of enrollment
Patient survival
1.00
Cumulative probability
0.75
0.50
p = 0.11, MMF vs IVCY
p = 0.02, AZA vs IVCY
p = 0.33, MMF vs AZA
0.25
19 19 15 10 9 4 2 AZA
20 19 12 6 3 2 1 IVCY
20 20 14 11 6 2 2 MMF
0.00
0 12 24 36 48 60 72
Time (months)
Free of relapse
1.00 p = 0.021, MMF vs IVCY
p = 0.124, AZA vs IVCY
p = 0.222, MMF vs AZA
Cumulative probability
0.75
0.50
0.25
19 15 10 6 4 3 1 AZA
17 10 4 2 2 1 1 IVCY
19 17 12 8 3 2 1 MMF
0.00
0 12 24 36 48 60 72
Time (months)
MMF vs. CTX for Lupus Nephritis
350 Patient Two-Phase study with a
6 month induction followed by up to
3 year maintenance
Euro-Lupus Nephritis Trial
Low-dose
All patients High-dose IV CYC IV CYC
Renal function (n = 85) (n = 44) (n = 41)
Normal 67 34 33
Permanently impaired 18 10 8
End-stage renal disease 4 3 1
Doubling of serum creatinine 8 1 7
Impaired renal function 6 6 0
Randomized (n = 370)
MMF IVC
Open-label treatment
Responders
Maintenance phase
Double-blind re-randomization to corticosteroids plus MMF or azathioprine for up to 3 years
Demographic Characteristics:
Intent-To-Treat Population
MMF IVC Total
(n = 185) (n = 185) (n = 370)
Male 28 (15.1) 29 (15.7) 57 (15.4)
Female 157 (84.9) 156 (84.3) 313 (84.6)
Ethnicity
Hispanic 64 (34.6) 67 (36.2) 131 (35.4)
Non-Hispanic 121 (65.4) 118 (63.8) 239 (64.6)
Race
White 75 (40.5) 72 (38.9) 147 (39.7)
Asian 62 (33.5) 61 (33.0) 123 (33.2)
Other 48 (25.9) 52 (28.1) 100 (27.0)
Black 26 (14.1) 20 (10.8) 46 (12.4)
Non-black other 22 (11.9) 32 (17.3) 54 (14.6)
Baseline Disease Characteristics by Race
(ITT Population)
Caucasian Black Asian Other
MMF IVC MMF IVC MMF IVC MMF IVC
(n=75) (n=72) (n=26) (n=20) (n=62) (n=61) (n=22) (n=32)
Min, Max 1.0, 3.3 1.5, 3.2 0.3, 6.8 1.8, 3.6
Number of IVC
infusions 71 18 60 31
Mean (SD) 5.8 (0.8) 4.8 (1.6) 5.6 (1.2) 5.7 (1.1)
Min, Max 1.0, 6.0 1.0, 6.0 1.0, 6.0 2.0, 7.0
Treatment Compliance
Oral MMF twice daily Oral corticosteroids twice daily
Mean (SD): 70 MMF
2.5 (0.58) (g/day) IVC
50
40
IVC in monthly pulses
30
Mean dose per
infusion: 20
0.78 g/m2 10
Mean (SD) doses per
0
month: 5.6 (1.1)
2 4 6 8 10 12 14 16 18 20 22 24
Week ending dosing period
Primary Endpoint:
Responders at Month 6
Response was judged by a blinded 100
Clinical Endpoint Committee, by the
60 56.2%
Decrease in urine protein/creatinine 53.0%
(%)
ratio (P/CR)
40
– to <3 in patients nephrotic at
baseline (P/CR ≥3), 20
– or by ≥50% in patients
subnephrotic at baseline (P/CR <3) 0
90
p = 0.575 p = 0.236 p = 0.834 p = 0.033
80
70 63.9
60.4
60 56.2 56.0 54.2
53.0 53.2
50
38.5
40
30
20
10
80
70
60.9 61.0
60 56.2
53.0 53.7
50
38.8
40
30
20
10
0
Overall Hispanic Non-Hispanic
Response by Region
100
Patients responding to treatment (%)
MMF
90 IVC
80
70 *
60
50
40
65.0% 67.6%
30 56.2% 53.0%
60.7% 56.6% 54.3%
52.6%
47.4%
20
32.0%
10
0
Overall Asia Latin America USA/Canada Rest of World
Key Renal
Secondary Endpoints
Complete remission as defined by:
1. return to normal serum creatinine level
2. proteinuria ≤500 mg/24 hr
3. inactive urinary sediment
Remission in each one of these individual
parameters
90
80 IVC (n = 185)
70.3% 67.6%
70
60
50
40 31.4%
30 23.8% 27.0% 23.8%
20
8.6% 8.1%
10
0
Complete Serum Urine protein Urine sediment
remission creatinine
100% 94%
40% N = 140
23% (Intent-
20% to-treat
6% analysis)
0%
Complete Remission Partial or No Remission
Complete remission defined as return to within 10% of normal values of serum creatinine, proteinuria, and urine sediment.
Source: Ginzler et al. NEJM. 2005; 353(21)
Importance of Maintaining
Complete Remission in Lupus Nephritis
Results of a long-term prospective study in patients with diffuse lupus nephritis
100% 92%
Patient survival without
80% ESRD less than 50% at 10
years with partial remission
Percentage of
Patients 60%
Surviving 43% P<0.0001 (CR vs PR)
Without ESRD 40%
20% 13%
0% N = 86
Complete Partial Remission No Remission
Remission
Partial Remission: 50% reduction in baseline proteinuria to < 1.5 g/d with not more than 25% increase in baseline sCr.
Complete Remission: Proteinuria < 0.33 g/d and serum creatinine < 1.4 mg/dl
Source: Chen et al. Clin J Am Soc Neph. 2008; 3(1)
Common Maintenance Therapies for Lupus Nephritis
Often Do Not Prevent Renal Flare
Contreras et al. Houssiau et al. Mok et al.
Study
NEJM. 2004; 350(10) A&R. 2004; 50(12) A&R. 2004;50(8)
Primarily Black and Hispanic Primarily Caucasian with Chinese patients with
Patient Type
with diffuse proliferative diffuse proliferative diffuse proliferative
nephritis (n=59) nephritis (n=89) nephritis (n=189)